Jazz Pharma Plc (JAZZ)

Jan 13, 2025, 12:56 PM EST - 4 days ago

3 Oversold Biotech Names

AVDL FOLD VKTX XBI

Dec 23, 2024, 12:53 PM EST - 25 days ago

Jazz Pharmaceuticals: Should Sing A Better Tune In 2025

Dec 17, 2024, 4:15 PM EST - 4 weeks ago

Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 16, 2024, 4:05 PM EST - 4 weeks ago

Jazz Pharmaceuticals Announces CEO Succession Plan

Dec 6, 2024, 4:05 PM EST - 6 weeks ago

Jazz Pharmaceuticals to Showcase New Real-World Evidence Reinforcing Epidiolex® (cannabidiol) Benefits and Broad-Spectrum Efficacy in Treatment-Resistant Epilepsies at the American Epilepsy Society 2024 Annual Meeting

Dec 5, 2024, 7:45 AM EST - 6 weeks ago

Jazz Pharmaceuticals Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii (Ziihera®)

Dec 4, 2024, 4:15 PM EST - 6 weeks ago

Jazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024

Dec 3, 2024, 7:49 AM EST - 6 weeks ago

Jazz Pharmaceuticals to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting

Nov 20, 2024, 7:59 PM EST - 2 months ago

Jazz Pharmaceuticals receives FDA approval for biliary tract cancer treatment

Nov 20, 2024, 7:19 PM EST - 2 months ago

Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

Nov 19, 2024, 4:05 PM EST - 2 months ago

Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference

Nov 6, 2024, 7:31 PM EST - 2 months ago

Jazz Pharmaceuticals plc (JAZZ) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 6:15 PM EST - 2 months ago

Jazz Pharmaceuticals Reports Strong Q3: Will Debt Weigh On Its Future Growth?

Nov 6, 2024, 4:05 PM EST - 2 months ago

Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results

Oct 31, 2024, 4:05 PM EDT - 2 months ago

Jazz Pharmaceuticals Presents New Data at Psych Congress 2024 Confirming Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Benefits in Narcolepsy and Idiopathic Hypersomnia

Oct 23, 2024, 4:15 PM EDT - 3 months ago

Jazz Pharmaceuticals to Report 2024 Third Quarter Financial Results on November 6, 2024

Oct 16, 2024, 8:39 AM EDT - 3 months ago

Jazz Pharmaceuticals: Unexpected Wins Improve The Long-Term Outlook

Oct 15, 2024, 11:50 AM EDT - 3 months ago

Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer

Oct 15, 2024, 7:30 AM EDT - 3 months ago

Jazz Pharmaceuticals Announces Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Oct 4, 2024, 9:00 AM EDT - 3 months ago

Jazz Pharmaceuticals: Unveiling Growth Potential From Non-Small Cell Lung Cancer Market

Sep 16, 2024, 7:30 AM EDT - 4 months ago

Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024

Sep 9, 2024, 7:58 AM EDT - 4 months ago

Jazz Pharmaceuticals to Present Advancements in Solid Tumor Oncology Research at ESMO 2024

Sep 5, 2024, 7:30 AM EDT - 4 months ago

Jazz Pharmaceuticals to Present New Data Demonstrating Improved Epilepsy Outcomes with Epidiolex®/Epidyolex® (cannabidiol) at the European Epilepsy Congress 2024

Sep 4, 2024, 12:00 AM EDT - 4 months ago

Jazz Pharmaceuticals Announces Pricing of Private Offering of $850 Million of 3.125% Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases

Sep 3, 2024, 7:00 AM EDT - 4 months ago

Jazz Pharmaceuticals Announces Private Offering of $850 Million of Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases

Aug 22, 2024, 4:05 PM EDT - 5 months ago

Jazz Pharmaceuticals Provides Update on Cannabidiol Oral Solution Phase 3 Trial in Japan in Treatment-Resistant Epilepsies

Aug 21, 2024, 4:15 PM EDT - 5 months ago

Jazz Pharmaceuticals to Participate in Upcoming September Investor Conferences

Jul 31, 2024, 7:40 PM EDT - 6 months ago

Jazz Pharmaceuticals plc (JAZZ) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 4:05 PM EDT - 6 months ago

Jazz Pharmaceuticals Announces Second Quarter 2024 Financial Results and Updates 2024 Financial Guidance

Jul 25, 2024, 4:05 PM EDT - 6 months ago

Jazz Pharmaceuticals Shareholders Elect Laura Hamill to the Company's Board of Directors at Annual General Meeting

Jul 22, 2024, 7:45 AM EDT - 6 months ago

Jazz Pharmaceuticals Announces Successful Completion of Term Loan Repricing and Irrevocable Election of Settlement Method for the 2.000% Exchangeable Senior Notes due 2026

Jul 17, 2024, 4:15 PM EDT - 6 months ago

Jazz Pharmaceuticals to Report 2024 Second Quarter Financial Results on July 31, 2024

Jul 9, 2024, 7:45 AM EDT - 6 months ago

Jazz Pharmaceuticals Promotes Samantha Pearce to Chief Commercial Officer

Jun 21, 2024, 9:15 AM EDT - 7 months ago

Jazz Pharmaceuticals: Pipeline Setback While Business Transition Continues

Jun 20, 2024, 12:29 PM EDT - 7 months ago

Why Is Jazz Pharmaceuticals Stock Trading Lower On Thursday?

Jun 20, 2024, 7:57 AM EDT - 7 months ago

Jazz Pharmaceuticals' tremor drug fails to meet main goal in mid-stage study

Jun 20, 2024, 7:45 AM EDT - 7 months ago

Jazz Pharmaceuticals Provides Update on Phase 2b Trial of Investigational Suvecaltamide (JZP385) in Essential Tremor

Jun 1, 2024, 8:05 AM EDT - 8 months ago

Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024

May 30, 2024, 7:30 AM EDT - 8 months ago

Jazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024

May 29, 2024, 4:15 PM EDT - 8 months ago

Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences

May 29, 2024, 7:45 AM EDT - 8 months ago

Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer

May 22, 2024, 8:00 AM EDT - 8 months ago

Jazz Pharmaceuticals Announces Collaboration with Life Science Cares to Improve the Wellbeing of Under Resourced Communities through Employee Volunteerism

May 1, 2024, 4:10 PM EDT - 9 months ago

Jazz Pharmaceuticals to Participate in the BofA Securities 2024 Health Care Conference

May 1, 2024, 4:05 PM EDT - 9 months ago

Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results and Affirms 2024 Financial Guidance

Apr 24, 2024, 4:05 PM EDT - 9 months ago

Jazz Pharmaceuticals to Present Data Across Growing Oncology Pipeline and Portfolio at ASCO 2024

Apr 17, 2024, 4:15 PM EDT - 9 months ago

Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024

Apr 15, 2024, 4:31 AM EDT - 9 months ago

Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off

Apr 10, 2024, 7:45 AM EDT - 10 months ago

Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual Meeting

Apr 2, 2024, 7:30 AM EDT - 10 months ago

Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer

Mar 12, 2024, 4:15 PM EDT - 11 months ago

Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024